Hydroxychloroquine

CAS No. 118-42-3

Hydroxychloroquine( —— )

Catalog No. M23351 CAS No. 118-42-3

Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 35 In Stock
200MG 50 In Stock
500MG 82 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Hydroxychloroquine
  • Note
    Research use only, not for human use.
  • Brief Description
    Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9.
  • Description
    Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    TLR7/9
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    118-42-3
  • Formula Weight
    335.87
  • Molecular Formula
    C18H26ClN3O
  • Purity
    >98% (HPLC)
  • Solubility
    1M HCl : 99 mg/mL (294.75 mM; adjust pH to 2 with HCl); H2O : 1.65 mg/mL (4.91 mM; ultrasonic and warming and heat to 60°C); DMSO : < 1 mg/mL (insoluble or slightly soluble)
  • SMILES
    CCN(CCCC(C)Nc1c(ccc(Cl)c2)c2ncc1)CCO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411-419.
molnova catalog
related products
  • CU-CPT-8m

    CU-CPT-8m is an toll-like receptor 8 (TLR8) antagonist (IC50 : 67 nM).

  • TLR7/8 agonist 1

    TLR7/8 agonist 1 is a toll-like receptor TLR7/TLR8 agonist with anticancer and antiviral activities and can be used to study immune-related diseases.

  • TLR7/8-IN-1

    TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor from patent WO2019220390 (compound 2b), is a valuable compound for autoimmune disease research.